NEA Management Company LLC Acquires 69,382 Shares of Mersana Therapeutics Inc (NASDAQ:MRSN)

NEA Management Company LLC raised its holdings in Mersana Therapeutics Inc (NASDAQ:MRSN) by 0.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,963,649 shares of the company’s stock after buying an additional 69,382 shares during the quarter. Mersana Therapeutics accounts for approximately 1.6% of NEA Management Company LLC’s holdings, making the stock its 20th biggest holding. NEA Management Company LLC owned approximately 25.02% of Mersana Therapeutics worth $18,903,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Marshall Wace LLP bought a new stake in shares of Mersana Therapeutics in the 1st quarter worth about $141,000. Sphera Funds Management LTD. bought a new stake in shares of Mersana Therapeutics in the 1st quarter worth about $1,052,000. Acadian Asset Management LLC bought a new stake in shares of Mersana Therapeutics in the 2nd quarter worth about $204,000. Russell Investments Group Ltd. grew its holdings in shares of Mersana Therapeutics by 41.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 13,900 shares of the company’s stock worth $56,000 after purchasing an additional 4,100 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in shares of Mersana Therapeutics in the 2nd quarter worth about $397,000. 83.57% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MRSN traded down $0.10 during trading hours on Friday, hitting $1.50. The stock had a trading volume of 358,095 shares, compared to its average volume of 352,265. The company’s fifty day moving average is $1.97 and its two-hundred day moving average is $3.75. The stock has a market capitalization of $69.32 million, a price-to-earnings ratio of -0.54 and a beta of 1.44. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.50 and a quick ratio of 5.50. Mersana Therapeutics Inc has a 52 week low of $1.40 and a 52 week high of $8.98.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.02. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 51.13%. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $1.08 million. Equities analysts predict that Mersana Therapeutics Inc will post -0.62 EPS for the current fiscal year.

Several research firms have recently weighed in on MRSN. Zacks Investment Research lowered shares of Mersana Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. ValuEngine raised shares of Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $10.17.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Read More: Cost of Goods Sold (COGS)

Want to see what other hedge funds are holding MRSN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mersana Therapeutics Inc (NASDAQ:MRSN).

Institutional Ownership by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply